Previous 10 | Next 10 |
2024-01-10 08:23:39 ET Losers: HWH International ( HWH ) -17% . Roma Green Finance Limited ( ROMA ) -19% . Aehr Test Systems AEHR -16% after Q2 earnings release . Denali Capital Acquisition Corp ( DECA ) -13% . ECD Automotive Design ( ...
2024-01-09 08:21:38 ET More on Pre-market losers $ stocks. Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript Cyclacel Pharmaceuticals announces registered direct and private placement offering Financial information for Aclarion, Inc. Seek...
2024-01-08 11:59:25 ET Vincerx Pharma ( NASDAQ: VINC ) shares jumped above 45% on Monday after the biopharmaceutical company reported positive efficacy data for a relapsed/refractory lymphoma combination therapy. Investigators from the National Institutes of Health obser...
2024-01-08 10:13:03 ET DENVER, Colo., Jan. 8, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Vincerx Pharma Inc (NASDAQ: VINC), Canoo Inc (NASDAQ: GOEV), Aclarion Inc (NASDAQ: ACON), Spectaire Holdings I...
2024-01-08 07:21:18 ET DENVER, Colo., Jan. 8, 2023 ( www.247marketnews.com )- Vincerx Pharma, Inc. (NASDAQ: VINC) published, Sunday evening, promising clinical results from a Phase 1 NIH-sponsored study of enitociclib in combination with venetoclax and prednisone for the treatment of re...
Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL) patients in ongoing dose-escalation trial of enitociclib in combination with venetoclax and ...
Poster on VIP943, a novel CD123-targeted antibody-drug conjugate (ADC) from our VersAptx ™ platform, showcases selectivity, activity, and safety of VIP943 Poster on VIP924, a first-in-class CXCR5-targeted ADC from our VersAptx platform, shows superior activity and safety compar...
2023-11-14 09:16:51 ET More on Vincerx Pharma Vincerx gains as FDA clears trial for blood cancer candidate Seeking Alpha’s Quant Rating on Vincerx Pharma Historical earnings data for Vincerx Pharma Financial information for Vincerx Pharma For f...
Phase 1 dose escalation for VIP943 - first antibody-drug conjugate (ADC) from VersAptx™ , versatile and adaptable, next-generation bioconjugation platform - moves quickly into 2 nd cohort Phase 1 dose escalation for VIP236 - first-in-class small molecule-drug conj...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
News, Short Squeeze, Breakout and More Instantly...
Vincera Pharma Inc Com Company Name:
VINC Stock Symbol:
NASDAQ Market:
Vincera Pharma Inc Com Website:
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The National Institutes of Health (NIH) and Vincerx announced positive result...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,000,000 shares of common stock,...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warra...